Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis

摘要: Temozolomide (TMZ) has received much attention, notably in the treatment of malignant glioma and melanoma. The objective this study was to compare clinical efficacy safety TMZ alone TMZ-based combination drug therapy patients with Using “temozolomide” as a keyword combined “melanoma” “randomized controlled trials” Medical Subject Headings, following electronic databases were searched: Cochrane library, MEDLINE, EBSCO, EMBASE, Ovid, cNKI, cBMDisc. evaluating indicators overall response rate (ORR), 1-year survival rate, several most frequent adverse events. Five randomized trials met our criteria included meta-analysis, total 703 participants (309 alone, 394 regimens). meta-analysis showed that ORR for higher than [relative risk (RR) = 1.44; 95 % confidence interval (CI), 1.06–1.95], but not significantly different between two groups (RR 1.13; CI, 0.92–1.40). These results suggested impact these increased rates translated into benefit. Moreover, we found no difference incidence events analyzed. currently available evidence TMZ-combination may moderately improve there corresponding toxicity. Future large-scale, high-quality, placebo-controlled, double-blind are needed.